ARDS is an acute, severe lung injury that causes edema of the lung alveoli, leading to breathing abnormalities and insufficient oxygen levels in the circulating blood, which may be life-threatening owing to respiratory failure and/or multi-organ dysfunction. ARDS may be caused by sepsis, trauma, severe pneumonia, or inhalation of harmful substances and it is associated with a high mortality rate. No pharmacological therapy is specifically approved for ARDS and treatment is supportive, principally comprising nonpharmacological approaches (e.g., mechanical ventilation, oxygen supplementation). There is unmet need and thus commercial opportunity for effective pharmacotherapies that can reduce patients’ reliance on ventilation and the mortality associated with ARDS. There are no therapies in late stages of development for ARDS, and the pipeline comprises largely early- to mid-stage agents with diverse mechanisms of action (e.g., Apeptico/Mediolanum Farmaceutici’s sodium channel modulator solnatide).


  • How will the size of the ARDS population change through 2026?
  • What are the key drug targets emerging from basic and clinical research in ARDS? Which emerging therapies do ARDS experts consider most promising? How would new therapies influence management of ARDS patients?
  • How are emerging ARDS drugs being evaluated, and which are likely to launch by 2026? What commercial impact will they have on the ARDS market?


Niche & Rare Disease Landscape & Forecast: Comprehensive market intelligence providing world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.

Table of contents

  • Acute Respiratory Distress Syndrome - Landscape & Forecast - Disease Landscape & Forecast

Author(s): Akash Saini, Ph.D.

Akash is a Principal Analyst in the China In-Depth team at Decision Resources Group. Since 2016, he has specialized in a range of indications including rare disease indications such as DMD, ALS, ITP, IPF, JIA, and retinitis pigmentosa. He has authored Disease Landscape & Forecast reports, Access & Reimbursement reports, and Treatment Algorithm reports based on primary market research and real-world evidence. Prior to joining DRG, Akash was a post-doctoral fellow at the University of Massachusetts Medical School. He has a Ph.D. from the International Centre for Genetic Engineering and Biotechnology, New Delhi.

Related Reports

Biosimilars - Market Events And Forecast - Respiratory

In 2018, sales of branded biologics in respiratory indications exceeded $1.5 billion across the major markets (United States, EU5, and Japan)....

View Details

Allergic Rhinitis - Special Topics - Allergic Respiratory Disorders | Special Topics | US

Allergic respiratory disorders—such as allergic rhinitis, chronic rhinosinusitis, and nasal polyps—are characterized by activation of inflammatory pathways and the production of immunog...

View Details